Insider Buying: Anixa Biosciences Inc (NASDAQ:ANIX) Director Purchases 10,000 Shares of Stock

Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. acquired 10,000 shares of the business's stock in a transaction that occurred on Friday, July 11th. The stock was acquired at an average cost of $3.14 per share, with a total value of $31,400.00. Following the completion of the acquisition, the director owned 943,334 shares in the company, valued at $2,962,068.76. This trade represents a 1.07% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Anixa Biosciences Stock Up 2.7%

Shares of NASDAQ ANIX traded up $0.09 during mid-day trading on Friday, reaching $3.44. 76,354 shares of the company were exchanged, compared to its average volume of 105,448. Anixa Biosciences Inc has a 52 week low of $2.07 and a 52 week high of $4.20. The stock has a market capitalization of $110.80 million, a PE ratio of -9.05 and a beta of 0.39. The company's 50 day moving average price is $3.05 and its 200 day moving average price is $2.88.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its quarterly earnings data on Tuesday, June 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. On average, sell-side analysts predict that Anixa Biosciences Inc will post -0.41 earnings per share for the current year.

Institutional Trading of Anixa Biosciences

A number of hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its holdings in shares of Anixa Biosciences by 36.5% during the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock worth $34,000 after acquiring an additional 3,900 shares during the last quarter. Millennium Management LLC purchased a new position in Anixa Biosciences in the 4th quarter worth $26,000. LPL Financial LLC lifted its stake in Anixa Biosciences by 37.2% in the fourth quarter. LPL Financial LLC now owns 42,937 shares of the company's stock worth $100,000 after purchasing an additional 11,633 shares during the last quarter. Private Advisor Group LLC bought a new position in shares of Anixa Biosciences during the first quarter valued at about $35,000. Finally, Jane Street Group LLC bought a new position in shares of Anixa Biosciences during the fourth quarter valued at about $67,000. 29.13% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on ANIX shares. Wall Street Zen raised shares of Anixa Biosciences from a "sell" rating to a "hold" rating in a report on Friday, June 6th. Maxim Group started coverage on shares of Anixa Biosciences in a report on Friday, March 21st. They issued a "buy" rating and a $10.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price objective on shares of Anixa Biosciences in a report on Tuesday, March 25th. Finally, D. Boral Capital reissued a "buy" rating and issued a $10.00 price target on shares of Anixa Biosciences in a report on Tuesday, June 10th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $9.00.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.